Immuno-Inflammatory Program

Synavive™ (CRx-102)

Synavive(CRx-102) can be broadly defined as a dissociated steroid. With this product candidate, we seek to selectively amplify the potent immuno-modulatory activity of steroids, with reduced side effects, which is also known as a dissociated steroid.

Steroids of the corticosteroid class are prescribed for the treatment of immuno-inflammatory diseases. The utility of these drugs, however, is limited by their substantial, dose-dependent adverse side effects. Our dissociated steroid product candidate consists of a low-dose corticosteroid combined with a different second active ingredient which our prior clinical studies suggest enhances the low-dose steroid's anti-inflammatory and immuno-modulatory activities. This is without, we believe, a comparable increase in the steroid's adverse side effects.

Additional drug candidates for the treatment of immuno-inflammatory diseases are currently in preclinical development.